» Articles » PMID: 24231406

The Role of PH and Ring-opening Hydrolysis Kinetics on Liposomal Release of Topotecan

Overview
Specialty Pharmacology
Date 2013 Nov 16
PMID 24231406
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The use of liposomal delivery systems for the treatment of cancer has been extensively researched because of their passive targeting to the vasculature of solid tumors. While their potential to provide prolonged retention and high drug encapsulation is desirable for anticancer agents, a mechanistic understanding is required to optimize and design liposomal drug delivery systems capable of controllable release tailored to tumor type and patient. Topotecan (TPT) is a topoisomerase I inhibitor that undergoes reversible, pH-sensitive ring-opening hydrolysis. TPT may benefit from liposomal formulation using active loading strategies to generate low intravesicular pH to prolong drug retention and increase drug encapsulation. This paper develops a mathematical model to describe TPT's permeability as a function of pH by accounting for the drug's ionization state, membrane binding, and ring-opening interconversion kinetics. Studies were conducted to determine the acid dissociation constant of TPT's phenolic -OH and interconversion kinetics between TPT's lactone and carboxylate forms. Using the constants determined from these studies and release studies conducted at varying pH, permeability coefficients and membrane binding constants for each species of TPT were determined. Based on this model, three permeable species were observed. Interestingly, the two most permeable species were zwitterionic forms of TPT, and the permeability of the lactone zwitterion was comparable to that of the neutral form of another camptothecin analogue. Furthermore, release was affected by based-catalyzed interconversion kinetics between TPT's lactone and carboxylate forms. At neutral pH, release was rate-limited by formation of the TPT lactone from the ring-opened carboxylate form. Based on these findings, the developed model describing liposomal release of TPT may be used in the future to evaluate and optimize loading and subsequent release of liposomal TPT formulations utilizing active loading strategies.

Citing Articles

Targeting Mitochondria for Cancer Treatment.

Zorova L, Abramicheva P, Andrianova N, Babenko V, Zorov S, Pevzner I Pharmaceutics. 2024; 16(4).

PMID: 38675106 PMC: 11054825. DOI: 10.3390/pharmaceutics16040444.


Assessment of In Vitro Release Testing Methods for Colloidal Drug Carriers: The Lack of Standardized Protocols.

Gomez-Lazaro L, Martin-Sabroso C, Aparicio-Blanco J, Torres-Suarez A Pharmaceutics. 2024; 16(1).

PMID: 38258113 PMC: 10819705. DOI: 10.3390/pharmaceutics16010103.


Robust Inclusion Complex of Topotecan Comprised within a Rhodamine-Labeled β-Cyclodextrin: Competing Proton and Energy Transfer Processes.

Di Nunzio M, Douhal A Pharmaceutics. 2023; 15(6).

PMID: 37376069 PMC: 10303446. DOI: 10.3390/pharmaceutics15061620.


Insights into the Degradation of Polymer-Drug Conjugates by an Overexpressed Enzyme in Cancer Cells.

Figueiredo P, Gonzalez R, Carvalho A J Med Chem. 2023; 66(4):2761-2772.

PMID: 36787193 PMC: 9969400. DOI: 10.1021/acs.jmedchem.2c01781.


Lactone Stabilized by Crosslinked Cyclodextrin Metal-Organic Frameworks to Improve Local Bioavailability of Topotecan in Lung Cancer.

Xiong T, Guo T, He Y, Cao Z, Xu H, Wu W Pharmaceutics. 2023; 15(1).

PMID: 36678769 PMC: 9865350. DOI: 10.3390/pharmaceutics15010142.


References
1.
Drummond D, Noble C, Guo Z, Hayes M, Connolly-Ingram C, Gabriel B . Development of a highly stable and targetable nanoliposomal formulation of topotecan. J Control Release. 2009; 141(1):13-21. DOI: 10.1016/j.jconrel.2009.08.006. View

2.
Batist G, Gelmon K, Chi K, Miller Jr W, Chia S, Mayer L . Safety, pharmacokinetics, and efficacy of CPX-1 liposome injection in patients with advanced solid tumors. Clin Cancer Res. 2009; 15(2):692-700. DOI: 10.1158/1078-0432.CCR-08-0515. View

3.
Joguparthi V, Anderson B . Liposomal delivery of hydrophobic weak acids: enhancement of drug retention using a high intraliposomal pH. J Pharm Sci. 2007; 97(1):433-54. DOI: 10.1002/jps.21135. View

4.
Bruce J, Fine R, Canoll P, Yun J, Kennedy B, Rosenfeld S . Regression of recurrent malignant gliomas with convection-enhanced delivery of topotecan. Neurosurgery. 2011; 69(6):1272-9. PMC: 4940854. DOI: 10.1227/NEU.0b013e3182233e24. View

5.
Ceh , Lasic . A Rigorous Theory of Remote Loading of Drugs into Liposomes: Transmembrane Potential and Induced pH-Gradient Loading and Leakage of Liposomes. J Colloid Interface Sci. 1997; 185(1):9-18. DOI: 10.1006/jcis.1996.4555. View